40例高龄低免疫力血液病患者长期留置PICC管的护理

2015-01-10 MedSci MedSci原创

近日,解放军总医院南楼血液科研究人员发表论文,旨在分析40例高龄血液病患者长期(≥1年)留置PICC管的护理过程,为临床高龄低免疫力患者长期保留PICC管提供护理依据。研究指出,通过建立个人PICC管资料,与社区医院资源共享,为患者化疗间歇期带管出院或转科消除了顾虑,达到了个性化护理的目的,将护理延伸到了院后。该文发表在2014年第05期《中华保健医学杂志》上。 采用置管方式的选择(超声引

近日,解放军总医院南楼血液科研究人员发表论文,旨在分析40例高龄血液病患者长期(≥1年)留置PICC管的护理过程,为临床高龄低免疫力患者长期保留PICC管提供护理依据。研究指出,通过建立个人PICC管资料,与社区医院资源共享,为患者化疗间歇期带管出院或转科消除了顾虑,达到了个性化护理的目的,将护理延伸到了院后。该文发表在2014年第05期《中华保健医学杂志》上。

采用置管方式的选择(超声引导、盲扎)、各种不良反应的预防及处理、日常维护、健康宣教、院内外信息共享机制的制定等护理措施。

经过上述方法的护理,40例患者均顺利使用PICC管完成化疗过程,且留置时间均大于管道说明规定时间(≥1年)、无1例管道相关感染发生、无1例堵管及脱管的发生,达到了长期带管全程无并发症的目标。

通过建立个人PICC管资料,与社区医院资源共享,为患者化疗间歇期带管出院或转科消除了顾虑,达到了个性化护理的目的,将护理延伸到了院后。

MedSci点评:

这篇研究的切入点很好,选择高龄低免疫力人群,这部分人群很容易发生感染,而PICC在置管方面较CVC可能有明显的优势,是比较不错的研究点。然而,这个研究还有很多缺陷:(1)这是回顾性研究;(2)高龄低免疫力的定义不足,需要有更严格的标准进行定义;(3)这是case serials,缺乏对照;因此,对于未发现相关感染,堵管的结论是很弱的(4)没有报告静脉血栓状况,这是读者十分关心的内容。(5)样本量如果再大一些,相对更好。因为PICC的并发症发生率比较低,在小样本下,可能观察不到。(6)结论超过本研究范围。

总之,如果就本立题,按上述说明进行改善,有望到国外期刊上发表。

原始出处:

40例高龄低免疫力血液病患者长期留置PICC管的护理。《中华保健医学杂志》 2014年05期,http://www.cnki.com.cn/Article/CJFDTotal-JFJB201405025.htm

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1670089, encodeId=db2716e008931, content=<a href='/topic/show?id=809ce0322c0' target=_blank style='color:#2F92EE;'>#留置#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70322, encryptionId=809ce0322c0, topicName=留置)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=532e26580241, createdName=xuyong532, createdTime=Sun Mar 08 01:21:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024143, encodeId=84ad20241431e, content=<a href='/topic/show?id=90af14258c5' target=_blank style='color:#2F92EE;'>#PICC管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14258, encryptionId=90af14258c5, topicName=PICC管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Apr 20 17:21:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307679, encodeId=b1e3130e67944, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414549, encodeId=04e9141454963, content=<a href='/topic/show?id=7c2b142565d' target=_blank style='color:#2F92EE;'>#PICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14256, encryptionId=7c2b142565d, topicName=PICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6b3060279, createdName=tomyang87, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416028, encodeId=f533141602866, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461993, encodeId=5e2f14619934f, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=)]
    2015-03-08 xuyong532
  2. [GetPortalCommentsPageByObjectIdResponse(id=1670089, encodeId=db2716e008931, content=<a href='/topic/show?id=809ce0322c0' target=_blank style='color:#2F92EE;'>#留置#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70322, encryptionId=809ce0322c0, topicName=留置)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=532e26580241, createdName=xuyong532, createdTime=Sun Mar 08 01:21:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024143, encodeId=84ad20241431e, content=<a href='/topic/show?id=90af14258c5' target=_blank style='color:#2F92EE;'>#PICC管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14258, encryptionId=90af14258c5, topicName=PICC管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Apr 20 17:21:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307679, encodeId=b1e3130e67944, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414549, encodeId=04e9141454963, content=<a href='/topic/show?id=7c2b142565d' target=_blank style='color:#2F92EE;'>#PICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14256, encryptionId=7c2b142565d, topicName=PICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6b3060279, createdName=tomyang87, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416028, encodeId=f533141602866, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461993, encodeId=5e2f14619934f, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=)]
    2015-04-20 zhouqu_8
  3. [GetPortalCommentsPageByObjectIdResponse(id=1670089, encodeId=db2716e008931, content=<a href='/topic/show?id=809ce0322c0' target=_blank style='color:#2F92EE;'>#留置#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70322, encryptionId=809ce0322c0, topicName=留置)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=532e26580241, createdName=xuyong532, createdTime=Sun Mar 08 01:21:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024143, encodeId=84ad20241431e, content=<a href='/topic/show?id=90af14258c5' target=_blank style='color:#2F92EE;'>#PICC管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14258, encryptionId=90af14258c5, topicName=PICC管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Apr 20 17:21:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307679, encodeId=b1e3130e67944, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414549, encodeId=04e9141454963, content=<a href='/topic/show?id=7c2b142565d' target=_blank style='color:#2F92EE;'>#PICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14256, encryptionId=7c2b142565d, topicName=PICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6b3060279, createdName=tomyang87, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416028, encodeId=f533141602866, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461993, encodeId=5e2f14619934f, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1670089, encodeId=db2716e008931, content=<a href='/topic/show?id=809ce0322c0' target=_blank style='color:#2F92EE;'>#留置#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70322, encryptionId=809ce0322c0, topicName=留置)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=532e26580241, createdName=xuyong532, createdTime=Sun Mar 08 01:21:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024143, encodeId=84ad20241431e, content=<a href='/topic/show?id=90af14258c5' target=_blank style='color:#2F92EE;'>#PICC管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14258, encryptionId=90af14258c5, topicName=PICC管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Apr 20 17:21:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307679, encodeId=b1e3130e67944, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414549, encodeId=04e9141454963, content=<a href='/topic/show?id=7c2b142565d' target=_blank style='color:#2F92EE;'>#PICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14256, encryptionId=7c2b142565d, topicName=PICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6b3060279, createdName=tomyang87, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416028, encodeId=f533141602866, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461993, encodeId=5e2f14619934f, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=)]
    2015-01-12 tomyang87
  5. [GetPortalCommentsPageByObjectIdResponse(id=1670089, encodeId=db2716e008931, content=<a href='/topic/show?id=809ce0322c0' target=_blank style='color:#2F92EE;'>#留置#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70322, encryptionId=809ce0322c0, topicName=留置)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=532e26580241, createdName=xuyong532, createdTime=Sun Mar 08 01:21:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024143, encodeId=84ad20241431e, content=<a href='/topic/show?id=90af14258c5' target=_blank style='color:#2F92EE;'>#PICC管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14258, encryptionId=90af14258c5, topicName=PICC管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Apr 20 17:21:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307679, encodeId=b1e3130e67944, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414549, encodeId=04e9141454963, content=<a href='/topic/show?id=7c2b142565d' target=_blank style='color:#2F92EE;'>#PICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14256, encryptionId=7c2b142565d, topicName=PICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6b3060279, createdName=tomyang87, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416028, encodeId=f533141602866, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461993, encodeId=5e2f14619934f, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=)]
    2015-01-12 xlysu
  6. [GetPortalCommentsPageByObjectIdResponse(id=1670089, encodeId=db2716e008931, content=<a href='/topic/show?id=809ce0322c0' target=_blank style='color:#2F92EE;'>#留置#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70322, encryptionId=809ce0322c0, topicName=留置)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=532e26580241, createdName=xuyong532, createdTime=Sun Mar 08 01:21:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024143, encodeId=84ad20241431e, content=<a href='/topic/show?id=90af14258c5' target=_blank style='color:#2F92EE;'>#PICC管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14258, encryptionId=90af14258c5, topicName=PICC管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Apr 20 17:21:00 CST 2015, time=2015-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307679, encodeId=b1e3130e67944, content=<a href='/topic/show?id=85d2289e188' target=_blank style='color:#2F92EE;'>#免疫力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28971, encryptionId=85d2289e188, topicName=免疫力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3547346, createdName=dongjia2010, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414549, encodeId=04e9141454963, content=<a href='/topic/show?id=7c2b142565d' target=_blank style='color:#2F92EE;'>#PICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14256, encryptionId=7c2b142565d, topicName=PICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6b3060279, createdName=tomyang87, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416028, encodeId=f533141602866, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461993, encodeId=5e2f14619934f, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jan 12 11:21:00 CST 2015, time=2015-01-12, status=1, ipAttribution=)]
    2015-01-12 docwu2019